title: The effect of mesenchymal stromal cells on doxorubicin-induced nephropathy in rats.
abstract: OBJECTIVE
  The potential protective effects of mesenchymal stromal cells (MSCs) on some kidney diseases has been reported. However, the effect of MSCs on doxorubicin-induced nephropathy is still poorly understood.
  
  
  METHODS
  Rats with doxorubicin-induced kidney injuries were treated with human cord-derived MSCs. Human MSCs were first labeled with 5-bromo-2'-deoxyuridine to track their homing in kidneys after infusion.
  
  
  RESULTS
  Alleviation of proteinuria, decreased serum albumin, alleviation of lipid disorders and histologic alterations were found in rats 4 weeks after treatment with MSCs, particularly in rats that were given repeat doses. Decreases in serum levels of interleukin-6, tumor necrosis factor-α and prostaglandin E2 and decreases in messenger RNA levels of kidney tissue cylooxygenase-2 and EP4 were found in MSC-treated rats. MSC-treated rats also displayed an increase in serum interleukin-10 levels.
  
  
  CONCLUSIONS
  These results indicate that MSCs ameliorate doxorubicin-induced kidney injuries and inflammation, suggesting a potential clinical treatment for inflammatory kidney diseases.
authors.affiliation: Department of Nephrology, Shenzhen People's Hospital, Second Clinical Medical College, Jinan University, Shenzhen, China.
authors.forename: Hualin
authors.initials: H
authors.lastname: Ma
authors.forename: Yaojiong
authors.initials: Y
authors.lastname: Wu
authors.forename: Wanfan
authors.initials: W
authors.lastname: Zhang
authors.forename: Yong
authors.initials: Y
authors.lastname: Dai
authors.forename: Furong
authors.initials: F
authors.lastname: Li
authors.forename: Ying
authors.initials: Y
authors.lastname: Xu
authors.forename: Yunshuai
authors.initials: Y
authors.lastname: Wang
authors.forename: Huiying
authors.initials: H
authors.lastname: Tu
authors.forename: Wuxian
authors.initials: W
authors.lastname: Li
authors.forename: Xinzhou
authors.initials: X
authors.lastname: Zhang
mesh_terms: D000818:Animals; D064987:Cell- and Tissue-Based Therapy; D051546:Cyclooxygenase 2 / Q000097:blood; D015232:Dinoprostone / Q000097:blood; D004317:Doxorubicin / Q000633:toxicity; D015870:Gene Expression; D006801:Humans; D007249:Inflammation / Q000473:pathology / Q000628:therapy; D015850:Interleukin-6 / Q000097:blood; D007674:Kidney Diseases / Q000097:blood / Q000139:chemically induced / Q000473:pathology / Q000628:therapy*; D045164:Mesenchymal Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D059630:Mesenchymal Stem Cells / Q000166:cytology*; D051381:Rats; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D004317:Doxorubicin; D051546:Cyclooxygenase 2; D015232:Dinoprostone